Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset

May 11 2018

• By Mandy Jackson

LungCancerCells_1200x675

Related Content

Immunocore attracts Lilly in co-co deal

Jul 16 2014

IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns

Feb 02 2018

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies

Oct 19 2017

Related Companies

Eli Lilly and Company

ARMO BioSciences, Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

Additional Topics

Deals Business Strategies ImmunoOncology Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window